Diana Bharucha-Goebel1,2, Petra Kaufmann3. 1. Department of Neurology, Children's National Medical Center, Washington, DC, USA. diana.bharucha@nih.gov. 2. Neuromuscular and Neurogenetic Disorders of Childhoood Section (NNDCS)/NINDS/NIH, Bethesda, MD, USA. diana.bharucha@nih.gov. 3. National Center for Advancing Translational Sciences (NCATS)/NIH, Bethesda, MD, USA.
Abstract
PURPOSE OF REVIEW: Spinal muscular atrophy (SMA) is a genetic disorder of motor neurons in the anterior horns of the spinal cord and brainstem that results in muscle atrophy and weakness. SMA is an autosomal recessive disease linked to deletions of the SMN1 gene on chromosome 5q. Humans have a duplicate gene (SMN2) whose product can mitigate disease severity, leading to the variability in severity and age of onset of disease, and is therefore a target for drug development. RECENT FINDINGS: Advances in preclinical and clinical trials have paved the way for novel therapeutic options for SMA patients, including many currently in clinical trials. In 2016, the first treatment for SMA has been approved in the USA, an antisense oligonucleotide that increases full-length protein product derived from SMN2. The approval of a first treatment for SMA and the rapid advances in clinical trials provide the prospect for multiple approaches to disease modification. There are several other promising therapeutics in different stages of development, based on approaches such as neuroprotection, or gene therapy.
PURPOSE OF REVIEW: Spinal muscular atrophy (SMA) is a genetic disorderof motor neurons in the anterior horns of the spinal cord and brainstem that results in muscle atrophy and weakness. SMA is an autosomal recessive disease linked to deletions of the SMN1 gene on chromosome 5q. Humans have a duplicate gene (SMN2) whose product can mitigate disease severity, leading to the variability in severity and age of onset of disease, and is therefore a target for drug development. RECENT FINDINGS: Advances in preclinical and clinical trials have paved the way for novel therapeutic options for SMA patients, including many currently in clinical trials. In 2016, the first treatment for SMA has been approved in the USA, an antisense oligonucleotide that increases full-length protein product derived from SMN2. The approval of a first treatment for SMA and the rapid advances in clinical trials provide the prospect for multiple approaches to disease modification. There are several other promising therapeutics in different stages of development, based on approaches such as neuroprotection, or gene therapy.
Entities:
Keywords:
Clinical trials; Functional biomarkers; Gene therapy; Natural history; Newborn screening; Spinal muscular atrophy; Standard of care
Authors: Enrico Bertini; Eric Dessaud; Eugenio Mercuri; Francesco Muntoni; Janbernd Kirschner; Carol Reid; Anna Lusakowska; Giacomo P Comi; Jean-Marie Cuisset; Jean-Louis Abitbol; Bruno Scherrer; Patricia Sanwald Ducray; Jeppe Buchbjerg; Eduardo Vianna; W Ludo van der Pol; Carole Vuillerot; Thomas Blaettler; Paulo Fontoura Journal: Lancet Neurol Date: 2017-04-28 Impact factor: 44.182
Authors: Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar Journal: Mol Ther Date: 2014-10-31 Impact factor: 11.454
Authors: Ching H Wang; Richard S Finkel; Enrico S Bertini; Mary Schroth; Anita Simonds; Brenda Wong; Annie Aloysius; Leslie Morrison; Marion Main; Thomas O Crawford; Anthony Trela Journal: J Child Neurol Date: 2007-08 Impact factor: 1.987
Authors: Kathryn J Swoboda; Charles B Scott; Thomas O Crawford; Louise R Simard; Sandra P Reyna; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan L Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; John T Kissel Journal: PLoS One Date: 2010-08-19 Impact factor: 3.240
Authors: Petra Kaufmann; Michael P McDermott; Basil T Darras; Richard S Finkel; Douglas M Sproule; Peter B Kang; Maryam Oskoui; Andrei Constantinescu; Clifton L Gooch; A Reghan Foley; Michele L Yang; Rabi Tawil; Wendy K Chung; William B Martens; Jacqueline Montes; Vanessa Battista; Jessica O'Hagen; Sally Dunaway; Jean Flickinger; Janet Quigley; Susan Riley; Allan M Glanzman; Maryjane Benton; Patricia A Ryan; Mark Punyanitya; Megan J Montgomery; Jonathan Marra; Benjamin Koo; Darryl C De Vivo Journal: Neurology Date: 2012-10-17 Impact factor: 9.910
Authors: John T Kissel; Charles B Scott; Sandra P Reyna; Thomas O Crawford; Louise R Simard; Kristin J Krosschell; Gyula Acsadi; Bakri Elsheik; Mary K Schroth; Guy D'Anjou; Bernard LaSalle; Thomas W Prior; Susan Sorenson; Jo Anne Maczulski; Mark B Bromberg; Gary M Chan; Kathryn J Swoboda Journal: PLoS One Date: 2011-07-06 Impact factor: 3.240
Authors: Michelle A Farrar; Susanna B Park; Steve Vucic; Kate A Carey; Bradley J Turner; Thomas H Gillingwater; Kathryn J Swoboda; Matthew C Kiernan Journal: Ann Neurol Date: 2017-02-17 Impact factor: 10.422
Authors: Maria C Pera; Giorgia Coratti; Nicola Forcina; Elena S Mazzone; Mariacristina Scoto; Jacqueline Montes; Amy Pasternak; Anna Mayhew; Sonia Messina; Maria Sframeli; Marion Main; Robert Muni Lofra; Tina Duong; Danielle Ramsey; Sally Dunaway; Rachel Salazar; Lavinia Fanelli; Matthew Civitello; Roberto de Sanctis; Laura Antonaci; Leonardo Lapenta; Simona Lucibello; Marika Pane; John Day; Basil T Darras; Darryl C De Vivo; Francesco Muntoni; Richard Finkel; Eugenio Mercuri Journal: BMC Neurol Date: 2017-02-23 Impact factor: 2.474
Authors: Eugenio Mercuri; Richard Finkel; Jacqueline Montes; Elena S Mazzone; Maria Pia Sormani; Marion Main; Danielle Ramsey; Anna Mayhew; Allan M Glanzman; Sally Dunaway; Rachel Salazar; Amy Pasternak; Janet Quigley; Marika Pane; Maria Carmela Pera; Mariacristina Scoto; Sonia Messina; Maria Sframeli; Gian Luca Vita; Adele D'Amico; Marleen van den Hauwe; Serena Sivo; Nathalie Goemans; Petra Kaufmann; Basil T Darras; Enrico Bertini; Francesco Muntoni; Darryl C De Vivo Journal: Neuromuscul Disord Date: 2015-12-03 Impact factor: 4.296
Authors: Adelaine Kwun-Wai Leung; Yasushi Kondo; Daniel A Pomeranz Krummel; Jade Li; Stephen R Price; Anne-Marie M van Roon Journal: Crystals (Basel) Date: 2021-08-15 Impact factor: 2.589
Authors: Didu S T Kariyawasam; Arlene D'Silva; Cindy Lin; Monique M Ryan; Michelle A Farrar Journal: Front Neurol Date: 2019-08-19 Impact factor: 4.003
Authors: Rosamund C Smith; Martin S Cramer; Pamela J Mitchell; Jonathan Lucchesi; Alicia M Ortega; Eric W Livingston; Darryl Ballard; Ling Zhang; Jeff Hanson; Kenneth Barton; Shawn Berens; Kelly M Credille; Ted A Bateman; Virginia L Ferguson; Yanfei L Ma; Louis S Stodieck Journal: PLoS One Date: 2020-04-21 Impact factor: 3.240